Free Trial
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.02
+31.7%		$0.03
$0.01
▼
$6.66
$301K0.13224,392 shs1.40 million shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.16
$0.02
$0.00
▼
$0.21
$193K-16.551,308 shs11 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%+43.64%-21.00%-79.74%-99.69%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+1,296.40%+154,900.00%+1,296.40%+638.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.02
+31.7%		$0.03
$0.01
▼
$6.66
$301K0.13224,392 shs1.40 million shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.16
$0.02
$0.00
▼
$0.21
$193K-16.551,308 shs11 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%+43.64%-21.00%-79.74%-99.69%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+1,296.40%+154,900.00%+1,296.40%+638.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.06N/AN/A$2.46 per share0.01
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/AN/A-237.65%57.29%N/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19M-$123.25N/AN/AN/AN/A-1,554.34%-338.29%11/19/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
11.61%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
5.27%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
61.14 million1.10 millionNo Data
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13019.02 million5.44 millionNo Data
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
21.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news
April 3, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/virpax-pharmaceuticals-stock-plummets-on-nasdaq-delisting-news-93CH-3966072
Virpax Pharmaceuticals Inc trading halted, news pending
March 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-inc-trading-halted-news-pending-1034500708
Virpax reports positive results in Probudur dog study
March 20, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-reports-positive-results-in-probudur-dog-study-93CH-3935131
Virpax receives positive Probudur results for dose range study
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-receives-positive-probudur-results-for-dose-range-study-1034490634
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-announces-1-for-25-reverse-stock-split-1034494202
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
March 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-receives-positive-probudur-results-200100643.html
Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-files-to-sell-common-stock-and-warrants-no-amount-given-1034485903
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-explores-intranasal-mrna-vaccine-delivery-using-met/ar-AA1AGDwC
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-to-present-nes100-toxicity-study-at-major-toxicology-conference/ar-AA1AF8g0
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
March 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250307334228/en/virpax-looking-to-use-met-to-develop-intranasal-covid-vaccine/
Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)
March 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/analysts-conflicted-on-these-healthcare-names-clearside-biomedical-clsd-and-virpax-pharmaceuticals-vrpx-1034450215
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
March 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-nes100-presented-society-toxicology-210100662.html
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology
March 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/virpax-pharmaceuticals-applauds-successful-trial-of-molecular-envelope-technology/ar-AA1A7VRw
Virpax lauds Nanomerics’ MET study with no severe side effects
March 1, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-lauds-nanomerics-met-study-with-no-severe-side-effects-93CH-3897728
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-reports-positive-results-human-210100424.html
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250227128970/en/virpax-reports-positive-results-in-human-study-for-its-molecular-envelope-technology/
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
February 13, 2025  |  joplinglobe.comJ
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
February 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-confirms-results-with-u-s-army-with-probudur-1034358717
Virpax reports positive study results for pain management drug
February 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-reports-positive-study-results-for-pain-management-drug/ar-AA1z0EUb
Virpax Pharmaceuticals appoints new independent director
February 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-pharmaceuticals-appoints-new-independent-director/ar-AA1yywrg

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 10/2/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.02 +0.00 (+31.67%)
As of 10/2/2026 03:49 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

$0.16 0.00 (0.00%)
As of 10/2/2026

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas